ifosfamide has been researched along with Nausea in 54 studies
Nausea: An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Background To determine the feasibility and efficacy of olanzapine, which is approved by the Pharmaceuticals and Medical Devices Agency as multi acting receptor targeted antipsychotic agent of the thienobenzodiazepine class, for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients undergoing continuous five-day chemotherapy." | 9.27 | Feasibility of olanzapine, multi acting receptor targeted antipsychotic agent, for the prevention of emesis caused by continuous cisplatin- or ifosfamide-based chemotherapy. ( Akagi, T; Bun, S; Fujiwara, Y; Hayashi, Y; Makino, Y; Noguchi, E; Shimizu, C; Shimoi, T; Shimomura, A; Tamura, K; Yonemori, K; Yunokawa, M, 2018) |
| "To investigate the electronic anti-nausea instrument (EANI) combined with hydrochloride palonosetron for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy." | 9.19 | Phase II study on EANI combined with hydrochloride palonosetron for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. ( Guo, JX; Huang, XE; Liu, J; Liu, YC; Wei, W; Xiao, Y, 2014) |
| "Ifosfamide is a cornerstone of chemotherapy in bone and soft-tissue sarcoma." | 9.14 | Ambulatory administration of 5-day infusion ifosfamide+mesna: a pilot study in sarcoma patients. ( Alexandre, J; Anract, P; Billemont, B; Camps, S; Coriat, R; Goldwasser, F; Larousserie, F; Leconte, M; Mir, O; Ropert, S, 2010) |
| "The efficacy and feasibility of a novel sequential schedule of high-dose ifosfamide (HD-IFO) and full-dose epirubicin (EPI) with granulocyte colony-stimulating factor (G-CSF) was evaluated in adult patients with soft tissue sarcomas (STS)." | 9.09 | A phase II study of dose-intense ifosfamide plus epirubicin with hematopoietic growth factors for the treatment of patients with advanced soft tissue sarcomas; a novel sequential schedule. ( Cognetti, F; Gamucci, T; Nardi, M; Serrone, L; Zeuli, M, 2001) |
| "This Phase II trial of paclitaxel/ifosfamide included patients with bi-dimensionally measurable metastatic breast cancer in second or third relapse, following anthracycline-containing regimens; ECOG PS < 2, and adequate hepatic, cardiac, renal, and hematological functions." | 9.08 | Phase II trial of paclitaxel and ifosfamide as a salvage treatment in metastatic breast cancer. ( Amorim, WC; Ferreira-Filho, AF; Guimaraes, RC; Morici, AC; Murad, AM; Schwartsmann, G, 1997) |
| "The novel 5HT3 receptor antagonist GR38032F was evaluated in the control of emesis induced by the cyclophosphamide analogue ifosfamide." | 7.67 | The efficacy and safety of GR38032F in the prophylaxis of ifosfamide-induced nausea and vomiting. ( Challoner, T; Green, JA; Griggs, J; Hammond, P; Watkin, SW, 1989) |
| "Early results with ifosfamide plus mesna in soft tissue sarcoma showed an initial response rate of 38% in 42 patients." | 7.67 | Ifosfamide plus mesna with and without adriamycin in soft tissue sarcoma. ( Fisher, C; Harmer, C; McKinna, A; Westbury, G; Wiltshaw, E, 1986) |
| "In a prospective study, 18 evaluable patients with recurrent osteosarcoma were treated with ifosfamide, 1." | 7.67 | High-dose ifosfamide in advanced osteosarcoma. ( Berchtold, W; Cserhati, M; Kroner, T; Marti, C; Remagen, W; Varini, M, 1985) |
| "Eligible patients had unresectable bladder cancer, previously treated with one line of systemic chemotherapy." | 6.68 | Second line chemotherapy with ifosfamide as outpatient treatment for advanced bladder cancer. ( Pensa, F; Pronzato, P; Tani, F; Vaira, F; Vanoli, M; Vigani, A, 1997) |
| "Ondansetron is a 5-HT3 antagonist and its antiemetic properties have been established in adults receiving chemotherapy." | 6.67 | The efficacy and safety of ondansetron in the prophylaxis of cancer-chemotherapy induced nausea and vomiting in children. ( Hewitt, M; McQuade, B; Stevens, R, 1993) |
| "Background To determine the feasibility and efficacy of olanzapine, which is approved by the Pharmaceuticals and Medical Devices Agency as multi acting receptor targeted antipsychotic agent of the thienobenzodiazepine class, for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients undergoing continuous five-day chemotherapy." | 5.27 | Feasibility of olanzapine, multi acting receptor targeted antipsychotic agent, for the prevention of emesis caused by continuous cisplatin- or ifosfamide-based chemotherapy. ( Akagi, T; Bun, S; Fujiwara, Y; Hayashi, Y; Makino, Y; Noguchi, E; Shimizu, C; Shimoi, T; Shimomura, A; Tamura, K; Yonemori, K; Yunokawa, M, 2018) |
| "To investigate the electronic anti-nausea instrument (EANI) combined with hydrochloride palonosetron for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy." | 5.19 | Phase II study on EANI combined with hydrochloride palonosetron for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. ( Guo, JX; Huang, XE; Liu, J; Liu, YC; Wei, W; Xiao, Y, 2014) |
| "Ifosfamide is a cornerstone of chemotherapy in bone and soft-tissue sarcoma." | 5.14 | Ambulatory administration of 5-day infusion ifosfamide+mesna: a pilot study in sarcoma patients. ( Alexandre, J; Anract, P; Billemont, B; Camps, S; Coriat, R; Goldwasser, F; Larousserie, F; Leconte, M; Mir, O; Ropert, S, 2010) |
| "The efficacy and feasibility of a novel sequential schedule of high-dose ifosfamide (HD-IFO) and full-dose epirubicin (EPI) with granulocyte colony-stimulating factor (G-CSF) was evaluated in adult patients with soft tissue sarcomas (STS)." | 5.09 | A phase II study of dose-intense ifosfamide plus epirubicin with hematopoietic growth factors for the treatment of patients with advanced soft tissue sarcomas; a novel sequential schedule. ( Cognetti, F; Gamucci, T; Nardi, M; Serrone, L; Zeuli, M, 2001) |
| "Forty-eight patients with metastatic or locally advanced soft tissue sarcoma were, following the first cycle of a combination with doxorubicin 60 mg/m2, ifosfamide 7." | 5.08 | Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity. ( Bonichon, F; Bui, BN; Chevallier, B; Chevreau, C; Cupissol, D; Fargeot, P; Krakowski, I; Maugard-Louboutin, C; Peny, AM; Thyss, A, 1995) |
| "This Phase II trial of paclitaxel/ifosfamide included patients with bi-dimensionally measurable metastatic breast cancer in second or third relapse, following anthracycline-containing regimens; ECOG PS < 2, and adequate hepatic, cardiac, renal, and hematological functions." | 5.08 | Phase II trial of paclitaxel and ifosfamide as a salvage treatment in metastatic breast cancer. ( Amorim, WC; Ferreira-Filho, AF; Guimaraes, RC; Morici, AC; Murad, AM; Schwartsmann, G, 1997) |
| "To examine the influence of the proposed symptom cluster of fatigue, nausea and vomiting, and sleep disturbances on clinical outcomes defined as behavior changes, depression, and performance status in children and adolescents before and after receiving cisplatin, doxorubicin, or ifosfamide chemotherapy." | 3.76 | Symptom clusters in children and adolescents receiving cisplatin, doxorubicin, or ifosfamide. ( Gregurich, M; Hockenberry, MJ; Hooke, MC; Krull, K; McCarthy, K; Sambuco, G, 2010) |
| "The aim of this study was to investigate the severity and time-course of alterations in gastroduodenal and intestinal permeability in relation to nausea/emesis following administration of the highly emetogenic polydrug regimen IFADIC (ifosfamide, Adriamycin, dacarbazine) using a differential lactulose/mannitol absorption (SLM) test." | 3.71 | Alterations in intestinal permeability following the intensified polydrug-chemotherapy IFADIC (ifosfamide, Adriamycin, dacarbazine). ( Brodowicz, T; Fazeny-Dörner, B; Marosi, C; Muhm, M; Veitl, M; Vogelsang, H; Wenzel, C; Zielinski, C, 2002) |
| "The novel 5HT3 receptor antagonist GR38032F was evaluated in the control of emesis induced by the cyclophosphamide analogue ifosfamide." | 3.67 | The efficacy and safety of GR38032F in the prophylaxis of ifosfamide-induced nausea and vomiting. ( Challoner, T; Green, JA; Griggs, J; Hammond, P; Watkin, SW, 1989) |
| "Early results with ifosfamide plus mesna in soft tissue sarcoma showed an initial response rate of 38% in 42 patients." | 3.67 | Ifosfamide plus mesna with and without adriamycin in soft tissue sarcoma. ( Fisher, C; Harmer, C; McKinna, A; Westbury, G; Wiltshaw, E, 1986) |
| "In a prospective study, 18 evaluable patients with recurrent osteosarcoma were treated with ifosfamide, 1." | 3.67 | High-dose ifosfamide in advanced osteosarcoma. ( Berchtold, W; Cserhati, M; Kroner, T; Marti, C; Remagen, W; Varini, M, 1985) |
| "Nineteen patients with progressive ovarian cancer following a cisplatin-based induction chemotherapy were treated with continuous infusion ifosfamide with mesna at 1 g/m2/d and 400 mg/m2/d, respectively, for seven days every 28 days." | 2.68 | Ifosfamide seven-day infusion for recurrent and cisplatin refractory ovarian cancer. ( Beuzeboc, P; Dorval, T; Garcia-Giralt, E; Jouve, M; Livartowski, A; Mosseri, V; Palangié, T; Pouillart, P; Sastre, X; Scholl, S; Soussain, C, 1996) |
| "A preliminary co-operative study by 7 institutes was conducted to determine the optimal dosage of the combination regimen with nedaplatin, bleomycin and ifosfamide, which is used in a phase III clinical study, to investigate its efficacy as neoadjuvant chemotherapy against advanced cervical cancer of the uterus." | 2.68 | [Combination chemotherapy with nedaplatin, bleomycin and ifosfamide for advanced cervical cancer of the uterus--a preliminary study for phase III clinical study]. ( Hatae, M; Hirabayashi, K; Kanazawa, K; Noda, K; Ozaki, M; Terashima, Y; Yakushiji, M, 1997) |
| "Eligible patients had unresectable bladder cancer, previously treated with one line of systemic chemotherapy." | 2.68 | Second line chemotherapy with ifosfamide as outpatient treatment for advanced bladder cancer. ( Pensa, F; Pronzato, P; Tani, F; Vaira, F; Vanoli, M; Vigani, A, 1997) |
| "Levels of depression were lower and showed little change." | 2.67 | A randomised trial of three or six courses of etoposide cyclophosphamide methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC). II: Quality of life. Medical Research Council Lung Cancer Working Party. ( Bleehen, NM; Girling, DJ; Machin, D; Stephens, RJ, 1993) |
| "Ondansetron is a 5-HT3 antagonist and its antiemetic properties have been established in adults receiving chemotherapy." | 2.67 | The efficacy and safety of ondansetron in the prophylaxis of cancer-chemotherapy induced nausea and vomiting in children. ( Hewitt, M; McQuade, B; Stevens, R, 1993) |
| "Patients with hormone-unresponsive prostate cancer were scheduled to receive CDDP 70 mg/m2 intravenously on day 1 and IFM 1." | 2.40 | [Combination chemotherapy with cis-platinum and ifosfamide for hormone unresponsive prostate cancer]. ( Asahi, T; Hata, K; Katayama, Y; Kobashi, K; Kobuke, M; Kondo, K; Kumon, H; Maki, Y; Nanba, K; Nasu, Y; Ochi, J; Ohashi, T; Ohmori, H; Ozaki, Y; Saegusa, M; Saika, T; Tanahashi, T; Tsushima, T; Uno, S; Yamashita, Y, 1998) |
| " In the previous five cycles of ifosfamide, carboplatin, and etoposide, the patient had no problems with the neurotoxic adverse effects associated with ifosfamide use." | 1.35 | Possible contribution of aprepitant to ifosfamide-induced neurotoxicity. ( Jarkowski, A, 2008) |
| " The bioavailability is nearly 100% after oral application, and the main metabolites are 4-hydroxytrofosfamide, and 4-hydroxyifosfamide." | 1.32 | Hypersensitivity pneumonitis associated with the use of trofosfamide. ( Hartmann, JT; Kanz, L; Kopp, HG, 2004) |
| "Ifosfamide chemotherapy was studied in 20 patients with advanced pancreatic carcinoma." | 1.30 | [Ifosfamide chemotherapy ineffective for advanced pancreatic carcinoma]. ( Akazawa, S; Fujiki, T; Futatsuki, K; Kanda, Y; Suda, Y; Terashi, K; Yamamoto, K; Yamato, A, 1997) |
| "The course of 72 patients (36 with squamous carcinoma, 25 with adenocarcinoma, two with alveolar-cell carcinoma and nine with large-cell carcinoma) could be evaluated." | 1.27 | [Chemotherapy of the non-small cell carcinoma of the lung with ifosfamide and cisplatin]. ( Abel, U; Dirks, HP; Drings, P; Grimm, V; Heinrich, S; Kleckow, M; Manke, HG; Queisser, W; Stiefel, P, 1984) |
| "Ifosfamide was administered to 21 patients with recurrent or disseminated lung cancer at a dose of 4." | 1.26 | Ifosfamide in the treatment of recurrent or disseminated lung cancer: a phase II study of two dose schedules. ( Costanzi, JJ; Gagliano, R; Hokanson, JA; Loukas, D; Panettiere, FJ, 1978) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 15 (27.78) | 18.7374 |
| 1990's | 16 (29.63) | 18.2507 |
| 2000's | 16 (29.63) | 29.6817 |
| 2010's | 7 (12.96) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bun, S | 1 |
| Yonemori, K | 1 |
| Akagi, T | 2 |
| Noguchi, E | 1 |
| Shimoi, T | 1 |
| Shimomura, A | 1 |
| Yunokawa, M | 1 |
| Shimizu, C | 1 |
| Fujiwara, Y | 1 |
| Makino, Y | 1 |
| Hayashi, Y | 1 |
| Tamura, K | 1 |
| Blay, JY | 1 |
| Leahy, MG | 1 |
| Nguyen, BB | 1 |
| Patel, SR | 1 |
| Hohenberger, P | 1 |
| Santoro, A | 1 |
| Staddon, AP | 1 |
| Penel, N | 1 |
| Piperno-Neumann, S | 1 |
| Hendifar, A | 1 |
| Lardelli, P | 1 |
| Nieto, A | 1 |
| Alfaro, V | 1 |
| Chawla, SP | 1 |
| Xiao, Y | 1 |
| Liu, J | 1 |
| Liu, YC | 1 |
| Huang, XE | 1 |
| Guo, JX | 1 |
| Wei, W | 1 |
| Kusaba, H | 1 |
| Kumagai, H | 1 |
| Inadomi, K | 1 |
| Matsunobu, T | 1 |
| Harimaya, K | 1 |
| Takayoshi, K | 1 |
| Arita, S | 1 |
| Ariyama, H | 1 |
| Akashi, K | 1 |
| Baba, E | 1 |
| Higgins, SC | 1 |
| Zakashansky, K | 1 |
| Bovbjerg, DH | 1 |
| Hagopian, G | 1 |
| Jarkowski, A | 1 |
| Liu, XM | 1 |
| Wang, HQ | 1 |
| Zhang, HL | 1 |
| Qiu, LH | 1 |
| Li, W | 1 |
| Li, LF | 1 |
| Cui, XZ | 1 |
| Liu, PF | 1 |
| Hao, XS | 1 |
| Shiu, JR | 1 |
| Romanick, M | 1 |
| Stobart, K | 1 |
| Coriat, R | 1 |
| Mir, O | 1 |
| Camps, S | 1 |
| Ropert, S | 1 |
| Billemont, B | 1 |
| Leconte, M | 1 |
| Larousserie, F | 1 |
| Anract, P | 1 |
| Alexandre, J | 1 |
| Goldwasser, F | 1 |
| Hockenberry, MJ | 1 |
| Hooke, MC | 1 |
| Gregurich, M | 1 |
| McCarthy, K | 1 |
| Sambuco, G | 1 |
| Krull, K | 1 |
| Jordan, K | 1 |
| Jahn, F | 1 |
| Jahn, P | 1 |
| Behlendorf, T | 1 |
| Stein, A | 1 |
| Ruessel, J | 1 |
| Kegel, T | 1 |
| Schmoll, HJ | 1 |
| Huang, YH | 1 |
| Wen, XP | 1 |
| Hu, L | 1 |
| Kopp, HG | 1 |
| Kanz, L | 1 |
| Hartmann, JT | 1 |
| Lorent, N | 1 |
| De Leyn, P | 1 |
| Lievens, Y | 1 |
| Verbeken, E | 1 |
| Nackaerts, K | 1 |
| Dooms, C | 1 |
| Van Raemdonck, D | 1 |
| Anrys, B | 1 |
| Vansteenkiste, J | 1 |
| Hayakawa, T | 1 |
| Sato, M | 1 |
| Konaka, M | 1 |
| Makino, A | 1 |
| Hirohata, T | 1 |
| Totsu, S | 1 |
| Wada, Y | 1 |
| Sato, H | 1 |
| Inotsume, N | 1 |
| Fujita, A | 1 |
| Sekine, K | 1 |
| Li, EX | 1 |
| Zhang, YT | 1 |
| Shang, JT | 1 |
| Xu, Z | 1 |
| Geng, Y | 1 |
| Li, SM | 1 |
| Shi, F | 1 |
| Wu, YY | 1 |
| Bo, LJ | 1 |
| Liang, AB | 1 |
| Liu, B | 1 |
| Chen, YH | 1 |
| Wang, F | 1 |
| Jin, XP | 1 |
| Su, Y | 1 |
| Takenaka, M | 1 |
| Okamoto, Y | 1 |
| Ikeda, K | 1 |
| Hashimoto, R | 1 |
| Ueda, T | 1 |
| Kurokawa, N | 1 |
| Takagi, T | 1 |
| Uejima, E | 1 |
| Drings, P | 1 |
| Stiefel, P | 1 |
| Dirks, HP | 1 |
| Grimm, V | 1 |
| Kleckow, M | 1 |
| Manke, HG | 1 |
| Queisser, W | 1 |
| Abel, U | 1 |
| Heinrich, S | 1 |
| Costanzi, JJ | 3 |
| Morgan, LR | 2 |
| Hokanson, J | 1 |
| Holoye, PY | 2 |
| Anderson, T | 2 |
| Duelge, J | 2 |
| Hansen, RM | 2 |
| Ritch, PS | 2 |
| Harrison, EF | 1 |
| Hawke, JE | 1 |
| Hunter, HL | 1 |
| Plotkin, D | 1 |
| Tucker, WG | 1 |
| Worrall, PM | 1 |
| Bleehen, NM | 1 |
| Girling, DJ | 1 |
| Machin, D | 1 |
| Stephens, RJ | 1 |
| Bui, BN | 1 |
| Chevallier, B | 1 |
| Chevreau, C | 1 |
| Krakowski, I | 1 |
| Peny, AM | 1 |
| Thyss, A | 1 |
| Maugard-Louboutin, C | 1 |
| Cupissol, D | 1 |
| Fargeot, P | 1 |
| Bonichon, F | 1 |
| Cullen, MH | 2 |
| Hewitt, M | 1 |
| McQuade, B | 1 |
| Stevens, R | 1 |
| Dorval, T | 1 |
| Soussain, C | 1 |
| Beuzeboc, P | 1 |
| Garcia-Giralt, E | 1 |
| Jouve, M | 1 |
| Livartowski, A | 1 |
| Mosseri, V | 1 |
| Palangié, T | 1 |
| Scholl, S | 1 |
| Sastre, X | 1 |
| Pouillart, P | 1 |
| Fujiki, T | 1 |
| Futatsuki, K | 1 |
| Akazawa, S | 1 |
| Yamamoto, K | 1 |
| Kanda, Y | 1 |
| Yamato, A | 1 |
| Terashi, K | 1 |
| Suda, Y | 1 |
| Noda, K | 1 |
| Hirabayashi, K | 1 |
| Terashima, Y | 1 |
| Ozaki, M | 1 |
| Yakushiji, M | 1 |
| Hatae, M | 1 |
| Kanazawa, K | 1 |
| Murad, AM | 1 |
| Guimaraes, RC | 1 |
| Amorim, WC | 1 |
| Morici, AC | 1 |
| Ferreira-Filho, AF | 1 |
| Schwartsmann, G | 1 |
| Pronzato, P | 1 |
| Vigani, A | 1 |
| Pensa, F | 1 |
| Vanoli, M | 1 |
| Tani, F | 1 |
| Vaira, F | 1 |
| Glisson, B | 1 |
| Lee, JS | 1 |
| Palmer, J | 1 |
| Fossella, F | 1 |
| Shin, DM | 1 |
| Murphy, WK | 1 |
| Perez-Soler, R | 1 |
| Hong, WK | 1 |
| Pronk, LC | 1 |
| Schrijvers, D | 1 |
| Schellens, JH | 1 |
| de Bruijn, EA | 1 |
| Planting, AS | 1 |
| Locci-Tonelli, D | 1 |
| Groult, V | 1 |
| Verweij, J | 1 |
| van Oosterom, AT | 1 |
| Maki, Y | 1 |
| Tsushima, T | 2 |
| Nasu, Y | 2 |
| Kumon, H | 1 |
| Ohmori, H | 2 |
| Tanahashi, T | 1 |
| Nanba, K | 1 |
| Ohashi, T | 1 |
| Kondo, K | 1 |
| Saika, T | 1 |
| Asahi, T | 2 |
| Saegusa, M | 1 |
| Ozaki, Y | 2 |
| Yamashita, Y | 1 |
| Katayama, Y | 1 |
| Kobuke, M | 1 |
| Uno, S | 1 |
| Ochi, J | 1 |
| Kobashi, K | 1 |
| Hata, K | 1 |
| Han, JY | 1 |
| Kim, HK | 1 |
| Choi, BG | 1 |
| Moon, H | 1 |
| Hong, YS | 1 |
| Lee, KS | 1 |
| Dodd, PM | 1 |
| McCaffrey, JA | 1 |
| Hilton, S | 1 |
| Mazumdar, M | 1 |
| Herr, H | 1 |
| Kelly, WK | 1 |
| Icasiano, E | 1 |
| Boyle, MG | 1 |
| Bajorin, DF | 1 |
| Thurnher, D | 1 |
| Kornfehl, J | 1 |
| Burian, M | 1 |
| Gedlicka, C | 1 |
| Selzer, E | 1 |
| Quint, C | 1 |
| Neuchrist, C | 1 |
| Kornek, GV | 1 |
| Serrone, L | 1 |
| Zeuli, M | 1 |
| Gamucci, T | 1 |
| Nardi, M | 1 |
| Cognetti, F | 1 |
| Fazeny-Dörner, B | 1 |
| Veitl, M | 1 |
| Wenzel, C | 1 |
| Brodowicz, T | 1 |
| Zielinski, C | 1 |
| Muhm, M | 1 |
| Vogelsang, H | 1 |
| Marosi, C | 1 |
| Gagliano, R | 1 |
| Loukas, D | 1 |
| Panettiere, FJ | 1 |
| Hokanson, JA | 1 |
| Scher, CS | 1 |
| Amar, D | 1 |
| McDowall, RH | 1 |
| Barst, SM | 1 |
| Lokich, I | 1 |
| Anderson, N | 1 |
| Bern, M | 1 |
| Moore, C | 1 |
| Falkson, G | 1 |
| Chasen, MR | 1 |
| Falkson, HC | 1 |
| Green, JA | 1 |
| Watkin, SW | 1 |
| Hammond, P | 1 |
| Griggs, J | 1 |
| Challoner, T | 1 |
| Chetiyawardana, SD | 1 |
| Joshi, RC | 1 |
| Woodroffe, CM | 1 |
| Meanwell, CA | 1 |
| Mould, JJ | 1 |
| Blackledge, G | 1 |
| Lawton, FG | 1 |
| Stuart, NS | 1 |
| Kavanagh, J | 1 |
| Latief, TN | 1 |
| Spooner, D | 1 |
| Chetiyawardana, AD | 1 |
| Wiltshaw, E | 1 |
| Westbury, G | 1 |
| Harmer, C | 1 |
| McKinna, A | 1 |
| Fisher, C | 1 |
| Gasparini, M | 1 |
| Ghosn, M | 1 |
| Droz, JP | 1 |
| Theodore, C | 1 |
| Pico, JL | 1 |
| Baume, D | 1 |
| Spielmann, M | 1 |
| Ostronoff, M | 1 |
| Moran, A | 1 |
| Salloum, E | 1 |
| Kramar, A | 1 |
| Einhorn, LH | 1 |
| Marti, C | 1 |
| Kroner, T | 1 |
| Remagen, W | 1 |
| Berchtold, W | 1 |
| Cserhati, M | 1 |
| Varini, M | 1 |
| Yoshimoto, J | 1 |
| Obama, T | 1 |
| Matsumura, Y | 1 |
| Ohkita, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Multicenter, Phase III Trial of Trabectedin (Yondelis) Versus Doxorubicin-based Chemotherapy as First-Line Therapy in Patients With Translocation-Related Sarcomas (TRS)[NCT00796120] | Phase 3 | 121 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| Sleep in Pediatric Hematopoietic Stem Cell Transplant Patients[NCT04106089] | 50 participants (Actual) | Interventional | 2019-11-18 | Completed | |||
| Aprepitant- and Olanzapine- Containing Regimens for Prevention of Acute and Delayed Nausea and Vomiting Associated With High Dose Melphalan and BEAM in Autologous Stem Cell Transplant Patients[NCT02939287] | Phase 3 | 429 participants (Actual) | Interventional | 2017-09-23 | Completed | ||
| Efficacy and Tolerance Adjuvant High-Dose Thiotepa With Peripheral Stem Cell Rescue Associated With Conventional Chemotherapy in Children and Adults With Relapsed Osteosarcoma[NCT00978471] | Phase 2 | 44 participants (Actual) | Interventional | 2009-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Percentage of participants survived for 6 months from the start of study treatment without progression of disease. Progression of the disease was associated with increasing symptoms, including pain from new or progressing lesions. Delay in disease progression generally represents a clinical benefit to the participant. (NCT00796120)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| Trabectedin | 66.7 |
| Doxorubicin Plus Ifosfamide | 78.3 |
The DOR is defined as the time from date of first documentation of response (CR or PR, whichever comes first) to the date of documented PD or death. PR=at least 30% reduction in the sum of the longest dimensions (LD) of all target lesions in reference to the baseline sum LD, CR =Disappearance of all non-target lesions. (NCT00796120)
Timeframe: Up to 20 months
| Intervention | days (Median) |
|---|---|
| Trabectedin | NA |
| Doxorubicin Plus Ifosfamide | NA |
Overall survival defined as time from the date of randomization to the date of death. For participants who were alive at the time of analysis, overall survival was censored at the last contact date. (NCT00796120)
Timeframe: Baseline up to End of Study (an average of 4 years)
| Intervention | months (Median) |
|---|---|
| Trabectedin | 46.6 |
| Doxorubicin Plus Ifosfamide | 33.5 |
Tumor response was assessed according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria: Partial Response (PR)=at least 30% reduction in the sum of the longest dimensions (LD) of all target lesions in reference to the baseline sum LD, Complete Response (CR) =Disappearance of all non-target lesions. Percentage of participants with objective tumor response was determined by the number of participants with PR or CR divided by the total number of response-evaluable participants. (NCT00796120)
Timeframe: Every 6 weeks during first 9 months of the study and thereafter every 9 weeks up to 20 months
| Intervention | percentage of participants (Number) |
|---|---|
| Trabectedin | 5.9 |
| Doxorubicin Plus Ifosfamide | 27.0 |
The PFS was assessed as median number of days from the date of randomization until the first documented sign of disease progression (increase in disease; radiographic, clinical, or both) or death due to any cause, whichever occurred earlier. (NCT00796120)
Timeframe: Every 6 weeks from randomization during the first 9 months and thereafter, every 9 weeks up to 20 months
| Intervention | months (Median) |
|---|---|
| Trabectedin | 19.6 |
| Doxorubicin Plus Ifosfamide | 8.3 |
1 review available for ifosfamide and Nausea
| Article | Year |
|---|---|
[Combination chemotherapy with cis-platinum and ifosfamide for hormone unresponsive prostate cancer].
Topics: Aged; Alopecia; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cis | 1998 |
24 trials available for ifosfamide and Nausea
| Article | Year |
|---|---|
Feasibility of olanzapine, multi acting receptor targeted antipsychotic agent, for the prevention of emesis caused by continuous cisplatin- or ifosfamide-based chemotherapy.
Topics: Adult; Antiemetics; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antipsych | 2018 |
Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Dioxoles; Doxorubicin; Drug Adm | 2014 |
Phase II study on EANI combined with hydrochloride palonosetron for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Carmustine; Cisplatin; Cyclophosphamide; Dacarbazin | 2014 |
[DNCE regimen for treatment of refractory or relapsed aggressive and highly aggressive non-Hodgkin lymphoma].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Pro | 2008 |
Ambulatory administration of 5-day infusion ifosfamide+mesna: a pilot study in sarcoma patients.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Drug Administration S | 2010 |
The NK-1 receptor-antagonist aprepitant in high-dose chemotherapy (high-dose melphalan and high-dose T-ICE: paclitaxel, ifosfamide, carboplatin, etoposide): efficacy and safety of a triple antiemetic combination.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Carboplatin; Drug Co | 2011 |
[Preliminary result of advanced soft tissue sarcoma treated by MAID regimen].
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Doxorubicin; Fem | 2002 |
Long-term survival of surgically staged IIIA-N2 non-small-cell lung cancer treated with surgical combined modality approach: analysis of a 7-year prospective experience.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell L | 2004 |
Use and safety of high-dose ifosfamide.
Topics: Adenocarcinoma; Aged; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Clinical Trials as Topic; Cyc | 1982 |
A randomised trial of three or six courses of etoposide cyclophosphamide methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC). II: Quality of life. Medical Research Council Lung Cancer Working Party.
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Anxiety; Carcinoma, Small Cel | 1993 |
Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Double-Blind Met | 1995 |
Mitomycin, ifosfamide, and cisplatin in non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Carcinoma, Non-Small-Cell | 1993 |
The efficacy and safety of ondansetron in the prophylaxis of cancer-chemotherapy induced nausea and vomiting in children.
Topics: Antineoplastic Agents; Child; Cisplatin; Female; Humans; Ifosfamide; Male; Nausea; Neoplasms; Ondans | 1993 |
Ifosfamide seven-day infusion for recurrent and cisplatin refractory ovarian cancer.
Topics: Adult; Aged; Alopecia; Ambulatory Care; Antineoplastic Agents, Alkylating; Female; Hematologic Disea | 1996 |
[Combination chemotherapy with nedaplatin, bleomycin and ifosfamide for advanced cervical cancer of the uterus--a preliminary study for phase III clinical study].
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow; Carci | 1997 |
Phase II trial of paclitaxel and ifosfamide as a salvage treatment in metastatic breast cancer.
Topics: Adult; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; F | 1997 |
Second line chemotherapy with ifosfamide as outpatient treatment for advanced bladder cancer.
Topics: Administration, Oral; Aged; Alopecia; Ambulatory Care; Antineoplastic Agents, Alkylating; Bone Marro | 1997 |
Cisplatin, ifosfamide, and prolonged oral etoposide in the treatment of patients with extensive small cell lung carcinoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineo | 1998 |
Phase I study on docetaxel and ifosfamide in patients with advanced solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Feasibility Studies; Female; | 1998 |
Quality of life (QOL) assessment of MIP (mitomycin, ifosfamide and cisplatin) chemotherapy in advanced non-small cell lung cancers (NSCLC).
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lun | 1998 |
Phase I evaluation of sequential doxorubicin gemcitabine then ifosfamide paclitaxel cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tract.
Topics: Aged; Agranulocytosis; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic | 2000 |
Ifosfamide and mitoxantrone in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Anemia; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 2001 |
A phase II study of dose-intense ifosfamide plus epirubicin with hematopoietic growth factors for the treatment of patients with advanced soft tissue sarcomas; a novel sequential schedule.
Topics: Adolescent; Adult; Aged; Alopecia; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemot | 2001 |
Ifosfamide continuous infusion without mesna. A phase I trial of a 14-day cycle.
Topics: Adult; Aged; Drug Administration Schedule; Drug Evaluation; Female; Hematuria; Humans; Ifosfamide; I | 1991 |
29 other studies available for ifosfamide and Nausea
| Article | Year |
|---|---|
Efficacy analysis of the aprepitant-combined antiemetic prophylaxis for non-round cell soft-tissue sarcoma patients received adriamycin and ifosfamide therapy.
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Do | 2016 |
Unexpected vomiting in a woman contemplating a second course of chemotherapy for carcinosarcoma of the uterus.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinosarcoma; Chemotherapy, Adjuvant; Cisplatin; F | 2008 |
Possible contribution of aprepitant to ifosfamide-induced neurotoxicity.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Carboplatin; Dexamet | 2008 |
Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in adolescents.
Topics: Adolescent; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Carboplatin; Ci | 2009 |
Symptom clusters in children and adolescents receiving cisplatin, doxorubicin, or ifosfamide.
Topics: Adolescent; Adolescent Behavior; Antineoplastic Agents; Attitude to Health; Child; Child Behavior; C | 2010 |
Hypersensitivity pneumonitis associated with the use of trofosfamide.
Topics: Administration, Oral; Aged; Alveolitis, Extrinsic Allergic; Antineoplastic Combined Chemotherapy Pro | 2004 |
[Comparison of ramosetron and azasetron for prevention of acute and delayed cisplatin-induced emesis in lung cancer patients].
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bridged Bi | 2006 |
[Effect of modified MAID regimen for patients with advanced soft tissue sarcoma].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Doxorubicin; F | 2006 |
[Efficacy of DICE (dexamethasone, etoposide, ifosfamide, and cisplatin) regimen on recurrent and refractory non-Hodgkin's lymphoma].
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 2006 |
[Efficacy of adriamycin, etoposide plus ifosfamide on small cell lung cancer--a retrospective analysis of 69 cases treated in Centre Hospitalo-Universitaire de Bordeaux].
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Doxorubi | 2006 |
[Comparison of antiemetic efficacy of 5-HT3 receptor antagonists in orthopedics cancer patients receiving high-dose chemotherapy].
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles | 2007 |
[Chemotherapy of the non-small cell carcinoma of the lung with ifosfamide and cisplatin].
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cisplatin; C | 1984 |
Ifosfamide in the treatment of extensive non-oat cell carcinoma of the lung.
Topics: Adenocarcinoma; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cyclophosphamide; Drug Administrati | 1982 |
Prophylaxis of ifosfamide toxicity with oral acetylcysteine.
Topics: Acetylcysteine; Adenocarcinoma; Aged; Carcinoma, Squamous Cell; Cyclophosphamide; Dose-Response Rela | 1983 |
Toxicity of single- vs. fractionated-dose ifosfamide in non-small cell lung cancer: a multi-center study.
Topics: Alopecia; Brain; Cyclophosphamide; Drug Administration Schedule; Drug Evaluation; Hematuria; Humans; | 1982 |
[Ifosfamide chemotherapy ineffective for advanced pancreatic carcinoma].
Topics: Adult; Aged; Anorexia; Antineoplastic Agents, Alkylating; Drug Administration Schedule; Female; Huma | 1997 |
Alterations in intestinal permeability following the intensified polydrug-chemotherapy IFADIC (ifosfamide, Adriamycin, dacarbazine).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Doxorubicin; Female; Human | 2002 |
Ifosfamide in the treatment of recurrent or disseminated lung cancer: a phase II study of two dose schedules.
Topics: Adenocarcinoma; Adult; Aged; Bone Marrow; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cyclophos | 1978 |
Use of propofol for the prevention of chemotherapy-induced nausea and emesis in oncology patients.
Topics: Adolescent; Adult; Antiemetics; Antineoplastic Agents; Bone Neoplasms; Cyclophosphamide; Female; Hum | 1992 |
Ifosfamide and mesna in combination with other cytostatic drugs in the treatment of patients with advanced cancer.
Topics: Adolescent; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small | 1990 |
The efficacy and safety of GR38032F in the prophylaxis of ifosfamide-induced nausea and vomiting.
Topics: Adult; Aged; Antiemetics; Drug Evaluation; Drug Tolerance; Female; Humans; Ifosfamide; Imidazoles; M | 1989 |
Ifosfamide, mitomycin and radiotherapy in non-small-cell lung cancer.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lun | 1989 |
Phase II study of ifosfamide in cervical cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Central Nervo | 1986 |
Ifosfamide plus mesna with and without adriamycin in soft tissue sarcoma.
Topics: Adolescent; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Pre | 1986 |
High-dose ifosfamide alone and in combination for solid malignancies in childhood.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cisplatin; Humans; Ifosfamide; Mesna; Nausea; | 1986 |
Salvage chemotherapy in refractory germ cell tumors with etoposide (VP-16) plus ifosfamide plus high-dose cisplatin. A VIhP regimen.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Choriocarcinoma; Cisplatin; Etopo | 1988 |
VP 16 plus ifosfamide plus cisplatin as salvage therapy in refractory testicular cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Evaluation; Humans; Ifosfamide; Kidn | 1986 |
High-dose ifosfamide in advanced osteosarcoma.
Topics: Alopecia; Bone Marrow; Cyclophosphamide; Humans; Ifosfamide; Nausea; Osteosarcoma; Prospective Studi | 1985 |
[Combination chemotherapy with cisplatin, ifosfamide and adriamycin in patients with advanced transitional cell carcinoma of the urinary tract].
Topics: Adult; Aged; Alopecia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transiti | 1985 |